ARK Genomic Revolution ETF $ARKG Shares Sold by Lauer Wealth LLC

Lauer Wealth LLC lessened its position in ARK Genomic Revolution ETF (BATS:ARKG) by 53.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 22,618 shares of the company’s stock after selling 25,600 shares during the period. ARK Genomic Revolution ETF makes up 0.4% of Lauer Wealth LLC’s investment portfolio, making the stock its 29th largest holding. Lauer Wealth LLC owned 0.05% of ARK Genomic Revolution ETF worth $628,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Private Wealth Asset Management LLC boosted its holdings in ARK Genomic Revolution ETF by 70.0% in the 2nd quarter. Private Wealth Asset Management LLC now owns 1,275 shares of the company’s stock valued at $31,000 after purchasing an additional 525 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new stake in shares of ARK Genomic Revolution ETF in the 2nd quarter valued at approximately $34,000. Strategic Wealth Investment Group LLC purchased a new stake in shares of ARK Genomic Revolution ETF in the second quarter valued at approximately $38,000. FWL Investment Management LLC grew its holdings in ARK Genomic Revolution ETF by 750.8% during the second quarter. FWL Investment Management LLC now owns 2,765 shares of the company’s stock worth $67,000 after acquiring an additional 2,440 shares during the period. Finally, Total Investment Management Inc. acquired a new position in ARK Genomic Revolution ETF during the second quarter worth $70,000.

ARK Genomic Revolution ETF Trading Up 22.8%

BATS:ARKG opened at $29.00 on Wednesday. ARK Genomic Revolution ETF has a 1 year low of $17.51 and a 1 year high of $31.16. The stock has a fifty day moving average price of $29.74 and a two-hundred day moving average price of $27.36.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.